The UK aesthetic injectable market has undergone a significant shift over the past decade. Korean-manufactured aesthetic products — botulinum toxins, hyaluronic acid fillers and skin boosters, PDRN polynucleotides, lipolytic agents, and now exosomes — have moved from being unfamiliar imports to becoming the preferred clinical tools of a growing proportion of UK aesthetic practitioners.

Discover the differences between exosomes and PDRN, what to expect from skincare and professional treatments, and how to choose an option that fits your skin goals.

The aesthetic exosome market is growing rapidly and unevenly. Alongside genuinely well-characterised, rigorously manufactured Korean products with transparent documentation, the market contains preparations making compelling regenerative claims while providing minimal evidence of their actual content, source, or regulatory classification. For practitioners, the ability to evaluate exosome products on scientific and regulatory grounds is essential.

Of all the aesthetic exosome applications currently in clinical use, post-procedure recovery support is the most evidence-consistent, the most mechanistically logical, and the most immediately valuable to patients.

Hair loss is one of the most emotionally significant concerns that patients bring to aesthetic practice. Androgenetic alopecia (AGA) — male and female pattern hair loss — affects an estimated 50% of men over 50 and up to 40% of women by age 70, making it one of the most prevalent aesthetic concerns across all demographics.

Exosomes are the most discussed new category in aesthetic medicine — and the category that most rewards a clear-eyed understanding of both the science and the considerable commercial noise that surrounds it.

Exosomes represent the most mechanistically sophisticated tool currently available for skin quality rejuvenation. Where hyaluronic acid skin boosters deliver hydration and PDRN activates the adenosine A2A receptor, MSC-derived exosomes deliver a complex biological payload — growth factors, microRNAs, and signalling proteins — directly into recipient skin cells

Injectable lipolytics produce permanent fat cell destruction in the treated zone — a genuine and valued clinical result. But in the vast majority of patients, fat reduction alone does not address the full picture of their concern. The neck that carries submental fat also typically has some degree of skin laxity and platysma banding. The inner thighs with localised fat often have a surface cellulite texture component. The abdomen after fat reduction may reveal skin laxity that was previously masked by the fat volume. In each of these situations, the lipolytic component treats one dimension while other treatments address the rest.

Two agents dominate injectable lipolytic practice: deoxycholic acid (DCA) as a single agent, and phosphatidylcholine combined with deoxycholic acid (PC/DCA) as a combination formulation. Both destroy subcutaneous fat cells, both produce the inflammatory clearance response that delivers the result, and both are available as CE-marked Korean formulations at Celmade. But they are not identical — and practitioners who understand the specific differences between them are better positioned to choose the right product for each clinical situation.

The submental zone is the best-evidenced and most widely discussed lipolytic application — but it is far from the only one. In international aesthetic practice, particularly in the Korean market where lipolytic treatments have been administered at high volume for over two decades, injectable lipolytics are used routinely across multiple body zones to address localised fat deposits that patients find resistant to diet and exercise and that significantly affect their confidence and comfort.

Submental fat reduction — the non-surgical treatment of the area beneath the chin that patients refer to as a 'double chin' — is the most evidence-supported, most precisely understood, and most widely practised injectable lipolytic application in aesthetic medicine. The zone has a defined fat compartment with reasonably predictable anatomy, a pharmaceutical-grade active agent with multiple Phase 3 RCTs behind it (deoxycholic acid, branded as Kybella/Belkyra), and a well-characterised safety profile built from extensive clinical experience.